ReviewFrontiers in immunology2023
Post kala-azar dermal leishmaniasis in the Indian sub-continent: challenges and strategies for elimination.
Review in Frontiers in immunology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 31 citations in OpenAlex.
- Postkala-Azar Dermal and Visceral Leishmaniasis in a Patient from Bangladesh.The American journal of tropical medicine and hygiene · 2026Article
- Post-kala-azar dermal leishmaniasis: insights into underlying pathogenic mechanisms and genetic landscape.Frontiers in microbiology · 2026Review
- The development of a global research agenda and individual participant data platform for visceral leishmaniasis: challenges and future opportunities.Parasites & vectors · 2025Article
- Leishmaniasis.Nature reviews. Disease primers · 2025Review
- Evaluation ofMicrobiology spectrum · 2025Article
- Exosomes in infectious diseases: insights into leishmaniasis pathogenesis, immune modulation, and therapeutic potential.Naunyn-Schmiedeberg's archives of pharmacology · 2025Review
- An Update on Clinical and Pathogenic Spectra of Leishmaniasis.Expert reviews in molecular medicine · 2025Review
- Plant-derived products as anti-leishmanials which target mitochondria: a review.Expert reviews in molecular medicine · 2025Review
- Patient insights research exploring disease awareness, patient life experience, and current management of visceral leishmaniasis in Bihar, India.PLoS neglected tropical diseases · 2025Article
- The Impact of Anthropic and Natural Events on Leishmaniasis Burden, Control Measures, and Public Health Importance.Transboundary and emerging diseases · 2025Review
- Progress in antileishmanial drugs: Mechanisms, challenges, and prospects.PLoS neglected tropical diseases · 2025Review
- Immunotherapeutic Strategies as Potential Treatment Options for Cutaneous Leishmaniasis.Vaccines · 2024Review
- Post-Kala-Azar Dermal Leishmaniasis.The American journal of tropical medicine and hygiene · 2024Article
- Emerging Leishmania donovani Lineages Associated with Cutaneous Leishmaniasis, Himachal Pradesh, India, 2023.Emerging infectious diseases · 2024Article
- Polyamine Metabolism for Drug Intervention in Trypanosomatids.Pathogens (Basel, Switzerland) · 2024Review
- The development and maintenance of immunity against visceral leishmaniasis.Frontiers in immunology · 2024Review
- Atypical cutaneous leishmaniasis: a new challenge to VL elimination in South-East Asia.Frontiers in cellular and infection microbiology · 2024Review
- Assessment of nutritional status among post-kala-azar dermal leishmaniasis patients in endemic areas of northern West Bengal, India.Tropical parasitologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Visceral leishmaniasis (VL) is a severe and often fatal form of leishmaniasis caused by
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.